article · BioMed Research International
An examination of 85 Enterobacteriaceae isolates from urinary tract infections in Gaza Strip hospitals revealed that 35.3 percent produced extended-spectrum beta-lactamases. Molecular characterisation identified bla CTX-M as the predominant beta-lactamase gene, followed by bla TEM, with CTX-M-15 representing 73 percent of all identified CTX-M variants. The insertion sequence ISEcp-1 was detected in 90 percent of the resistant isolates, whilst class 1 integrons containing various aadA and dfrA gene cassettes were present in 53.3 percent. The fluoroquinolone and aminoglycoside resistance determinant aac(6 prime)-Ib-cr was observed in 36.7 percent of the enzyme-producing isolates. The findings confirm the first regional detection of bla CTX-M-15 in Providencia rettgeri and Serratia liquefaciens, as well as bla CTX-M-37 in Enterobacter cloacae. Strains producing these enzymes showed broader resistance across tested antibiotics than non-producing counterparts.
Urinary tract infections caused by antibiotic-resistant bacteria present severe challenges to standard medical care because treatment options become strictly limited. Understanding the specific resistance genes and genetic mechanisms driving the spread of extended-spectrum beta-lactamases enables clinical laboratories and infection control teams to track hospital-acquired pathogens and adjust local antibiotic stewardship policies to mitigate therapeutic failures.
The abstract does not indicate an application pathway, as it reports early-stage epidemiological and genetic surveillance data without proposing a product, assay, or commercial development route.
AI-generated from the published abstract. Always read the original work before citing.
Background . Extended-spectrum β -lactamase-producing organisms causing urinary tract infections are increasing in incidence and pose a major impendence to health-care facility, having limited therapeutic options. This study aimed to assess the prevalence of ESBLs in Enterobacteriaceae isolates causing urinary tract infections in Gaza strip, Palestine, and to characterize β -lactamase types and associated resistance genes. Methods . Eighty-five Enterobacteriaceae isolates were recovered from urinary tract infections within three months in Gaza Strip hospitals. The characterization of β -lactamase genes and the genetic environments of CTX-M, the identification of associated resistance genes, and the presence and characterization of integrons were tested by PCR and sequencing. Results . The occurrence rate of ESBL among tested isolates was 30 (35.3%), and among ESBL-positive isolates, bla CTX-M was the highest followed by bla TEM . ESBL-CTX-M-1 group was confirmed in 93.3%, and the remaining carried CTX-M-9 group. CTX-M-15, CTX-M-3, CTX-M-1, CTX-M-14, CTX-M-27, and CTX-M-37 enzymes were demonstrated among the isolates with the majority (73%) being CTX-M-15. IS Ecp-1 was demonstrated in 27 (90%, high incidence) of ESBL isolates. Class 1 integrons have been detected in higher rates (53.3%) in ESBL-positive isolates in comparison with non-ESBL isolates (6, 33.3%). Cassettes of integron-1 contain ( aadA1 , aadA2 , aadA5 , dfrA5 , dfrA7 , dfrA12 , and dfrA17 ) genes. The aac(6′)-Ib-cr gene was demonstrated in 36.7% of ESBL-positive isolates. Conclusions . This study indicates that bla CTX-M-15 was the most prevalent β -lactamase in this region. Our study demonstrates for the first time in Palestine the identification of bla CTX-M-15 in P. rettgeri and S. liquefaciens , also bla CTX-M-37 in E. cloacae. The coexpression of multiple β -lactamase genes with aac(6′)-Ib-cr and qnr in the presence of IS Ecp-1 and integrons in individual strains will increase the dissemination of highly resistant strains. ESBL producers were more resistant than non-ESBLs producers for almost all tested antibiotics.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1155/2019/4041801
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
